tradingkey.logo
tradingkey.logo
Search

ADMA Biologics Inc

ADMA
Add to Watchlist
8.460USD
-0.210-2.42%
Close 07-31 16:00ETQuotes delayed by 15 min
1.96BMarket Cap
12.16P/E TTM

ADMA Biologics Inc

8.460
-0.210-2.42%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.42%

5 Days

+2.30%

1 Month

-5.47%

6 Months

-51.66%

Year to Date

-53.62%

1 Year

-56.23%

Key Figures
8.580Open
8.660High
1.62MVolume
12.16P/E TTM
7.85P/E Dynamic
--Dividend TTM
0.70%Turnover Ratio
8.670Prev. Close
8.350Low
10.70MTurnover
9.94P/E Static
5.03P/B
0.00%Div Yield TTM
28.13%ROA
22.37052wk High
0.84Volume Ratio
197.67MNet Profit
232.29MShares
0.6954EPS TTM
0.74Beta
43.30%ROE
7.21052wk Low
3.58%Amplitude
70.48%Gross Margin
1.96BMarket Cap
-1.75Reward/Risk
3.06%Risk Rate

TradingKey Stock Score of ADMA Biologics Inc

Currency: USD Updated: 2026-07-31

Key Insights

ADMA Biologics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 28 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ADMA Biologics Inc's Score

Industry at a Glance

Industry Ranking
28 / 155
Overall Ranking
78 / 4281
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

ADMA Biologics Inc Highlights

StrengthsRisks
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 97.58% year-on-year.
Fairly Valued
The company’s latest PE is 12.17, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 218.01M shares, decreasing 13.44% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.76M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.30.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
17.000
Target Price
+100.95%
Upside Space

ADMA Biologics Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 5 analysts
Buy
Current Rating
17.000
Target Price
+100.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
9
Average
Company name
Ratings
Analysts
ADMA Biologics Inc
ADMA
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32

Indicators

Indicators
Sell(4)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.040
Sell
RSI(14)
44.694
Neutral
STOCH(KDJ)(9,3,3)
54.072
Neutral
ATR(14)
0.272
High Vlolatility
CCI(14)
-57.440
Neutral
Williams %R
64.881
Sell
TRIX(12,20)
-0.058
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
8.622
Sell
MA10
8.547
Sell
MA20
8.769
Sell
MA50
8.491
Sell
MA100
9.662
Sell
MA200
13.343
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ADMA Biologics Inc Info

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Ticker SymbolADMA
CompanyADMA Biologics Inc
CEOGrossman (Adam S)
Websitehttps://www.admabiologics.com/

Shareholders

Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.40%
State Street Investment Management (US)
5.87%
Sachem Head Capital Management LP
4.91%
Vanguard Capital Management, LLC
4.45%
Invesco Advisers, Inc.
4.19%
Other
66.20%

FAQs

What is the current price of ADMA Biologics Inc (ADMA)?

The current price of ADMA Biologics Inc (ADMA) is 8.46.

What is the symbol of ADMA Biologics Inc?

The ticker symbol of ADMA Biologics Inc is ADMA.

What is the 52-week high of ADMA Biologics Inc?

The 52-week high of ADMA Biologics Inc is 22.37.

What is the 52-week low of ADMA Biologics Inc?

The 52-week low of ADMA Biologics Inc is 7.21.

What is the market capitalization of ADMA Biologics Inc?

The market capitalization of ADMA Biologics Inc is 1.96B.

Is ADMA Biologics Inc (ADMA) currently rated as Buy, Hold, or Sell?

According to analysts, ADMA Biologics Inc (ADMA) has an overall rating of Buy, with a price target of 17.00.

What is the Earnings Per Share (EPS TTM) of ADMA Biologics Inc (ADMA)?

The Earnings Per Share (EPS TTM) of ADMA Biologics Inc (ADMA) is 0.62.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.